PM20D1 is a quantitative trait locus associated with Alzheimer's disease.

Sanchez-Mut, Jose V; Heyn, Holger; Silva, Bianca A; Dixsaut, Lucie; Garcia-Esparcia, Paula; Vidal, Enrique; Sayols, Sergi; Glauser, Liliane et al. · Nat Med · 2018

basic_science · Level V

Where this comes from

Abstract

The chances to develop Alzheimer's disease (AD) result from a combination of genetic and non-genetic risk factors <sup>1</sup> , the latter likely being mediated by epigenetic mechanisms <sup>2</sup> . In the past, genome-wide association studies (GWAS) have identified an important number of risk loci associated with AD pathology <sup>3</sup> , but a causal relationship remains difficult to establish. In contrast, locus-specific or epigenome-wide association studies (EWAS) have revealed site-specific epigenetic alterations, which provide mechanistic insights for a particular risk gene but often lack the statistical power of GWAS <sup>4</sup> . Here, combining both approaches, we report a previously unidentified association of the peptidase M20-domain-containing protein 1 (PM20D1) with AD. We find that PM20D1 is a methylation and expression quantitative trait locus coupled to an AD-risk associated haplotype, which displays enhancer-like characteristics and contacts the PM20D1 promoter via a haplotype-dependent, CCCTC-binding-factor-mediated chromatin loop. Furthermore, PM20D1 is increased following AD-related neurotoxic insults at symptomatic stages in the APP/PS1 mouse model of AD and in human patients with AD who are carriers of the non-risk haplotype. In line, genetically increasing or decreasing the expression of PM20D1 reduces and aggravates AD-related pathologies, respectively. These findings suggest that in a particular genetic background, PM20D1 contributes to neuroprotection against AD.

Medical subject headings